Addex Therapeutics (ADXN) Receivables - Other (2018 - 2025)
Addex Therapeutics (ADXN) posted Receivables - Other of $72562.8 for Q2 2025, up 697.88% sequentially from $9094.5 in Q4 2024, and up 115.01% YoY from $33748.8 in Q2 2024.
Addex Therapeutics (ADXN) Receivables - Other (2018 - 2025) Analysis & Trends
Addex Therapeutics has reported Receivables - Other for 6 years, with the latest figure at $72562.8 in Q2 2025.
- Quarterly Receivables - Other rose 115.01% year-over-year to $72562.8 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $72562.8 (up 115.01% YoY) and the FY2024 annual result came in at $9056.1, down 80.36% from the prior year.
- Receivables - Other grew to $72562.8 in Q2 2025 per ADXN's latest filing, from $9094.5 in the prior quarter.
- Over five years, Receivables - Other peaked at $1.2 million in Q2 2021 and troughed at $9094.5 in Q4 2024.
- A 5-year average of $201336.0 and a median of $124651.4 in 2024 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2022 and 2023: Receivables - Other plunged 88.67% in 2022, then jumped 196.06% in 2023.
- Over 5 years, Receivables - Other stood at $140985.3 in 2021, then slipped by 11.65% to $124562.6 in 2022, then plunged by 62.98% to $46116.7 in 2023, then plunged by 80.28% to $9094.5 in 2024, then soared by 697.88% to $72562.8 in 2025.
- According to Business Quant data, Receivables - Other over the past three periods registered $72562.8, $9094.5, and $42130.9 for Q2 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 72,562.80 |
| Jun 30, 2025 | 72,562.80 |
| Dec 31, 2024 | 9,094.50 |
| Dec 31, 2024 | 9,094.50 |
| Sep 30, 2024 | 42,130.87 |
| Sep 30, 2024 | 42,130.87 |
| Jun 30, 2024 | 33,748.82 |
| Jun 30, 2024 | 33,748.82 |
| Mar 31, 2024 | 124,651.38 |
| Mar 31, 2024 | 124,651.38 |
| Dec 31, 2023 | 46,116.69 |
| Dec 31, 2023 | 46,116.69 |
| Sep 30, 2023 | 214,088.92 |
| Sep 30, 2023 | 214,088.92 |
| Jun 30, 2023 | 274,291.41 |
| Jun 30, 2023 | 274,291.41 |
| Mar 31, 2023 | 217,375.30 |
| Mar 31, 2023 | 217,375.30 |
| Dec 31, 2022 | 124,562.63 |
| Dec 31, 2022 | 124,562.63 |